A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Poland- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Ul. Ziolowa 45/47, 40-635 Katowice, Poland
Gornoslaskie Centrum Mwdyczne in Katowice, Poland specialises in clinical trials of conditions such as Atrial fibrillation, Ischaemic stroke, Acute coronary syndrome, Pulmonary arterial hypertension, and other specialisations. This site conducts important research.
The medical center is at the forefront of cardiology research, particularly in the development of innovative antithrombotic therapies for patients with atrial fibrillation (AF) who have undergone percutaneous coronary intervention (PCI). The center's research focuses on optimizing treatment regimens to enhance patient outcomes and minimize risks.
Through its pioneering studies, the center is contributing significantly to the understanding of how to balance efficacy and safety in antithrombotic therapy, potentially reshaping standard care practices for AF patients post-PCI.
Clinical trials currently enrolling participants at this site.
Poland
Poland
Poland
Poland
Poland
Poland
Poland
Poland
Poland
Poland
Poland
PolandMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.